Search results for "Cutaneous"

showing 10 items of 1022 documents

5-Year Experience of In-Hospital Outcomes After Percutaneous Left Atrial Appendage Closure in Germany

2019

The aim of this study was to evaluate 5-year in-hospital trends and safety outcomes of left atrial appendage (LAA) closure in the German nationwide inpatient sample.The safety and efficacy of percutaneous LAA closure have been demonstrated in randomized trials and prospective cohort studies, but results from large samples are missing.Data on patient characteristics and in-hospital safety outcomes for all percutaneous LAA closures performed in Germany between 2011 and 2015 were analyzed. Overall, 15,895 inpatients were included.The annual number of LAA occlusions increased from 1,347 in 2011 to 4,932 in 2015 (β = 1.00; 95% confidence interval [CI]: 0.95 to 1.01; p 0.001), with a nonsignifica…

MaleCardiac Catheterizationmedicine.medical_specialtyTime FactorsPercutaneousHealth StatusComorbidity030204 cardiovascular system & hematologyPericardial effusionlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialRisk FactorslawCause of DeathGermanyAtrial FibrillationHumansMedicineAtrial AppendageHospital Mortality030212 general & internal medicineProspective cohort studyStrokeAgedAged 80 and overbusiness.industryMortality rateAtrial fibrillationmedicine.diseaseConfidence intervalSurgeryTreatment OutcomeAtrial Function LeftFemaleCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Classical Flt3L-dependent dendritic cells control immunity to protein vaccine

2014

DCs are critical for initiating immunity. The current paradigm in vaccine biology is that DCs migrating from peripheral tissue and classical lymphoid-resident DCs (cDCs) cooperate in the draining LNs to initiate priming and proliferation of T cells. Here, we observe subcutaneous immunity is Fms-like tyrosine kinase 3 ligand (Flt3L) dependent. Flt3L is rapidly secreted after immunization; Flt3 deletion reduces T cell responses by 50%. Flt3L enhances global T cell and humoral immunity as well as both the numbers and antigen capture capacity of migratory DCs (migDCs) and LN-resident cDCs. Surprisingly, however, we find immunity is controlled by cDCs and actively tempered in vivo by migDCs. Del…

MaleCellular immunityInjections IntradermalLangerinOvalbuminInjections SubcutaneousT cellImmunologyAntigen presentationGene ExpressionPriming (immunology)Mice Transgenicchemical and pharmacologic phenomenaLigandsInterferon-gammaMice03 medical and health sciences0302 clinical medicineAntigenT-Lymphocyte SubsetsImmunitymedicineAnimalsHumansImmunology and AllergyLectins C-Type030304 developmental biologyMice KnockoutAntigen PresentationVaccines0303 health sciencesbiologyMembrane ProteinsProteinsDendritic Cellsbiochemical phenomena metabolism and nutritionImmunity Humoral3. Good healthMice Inbred C57BLMannose-Binding Lectinsmedicine.anatomical_structureAntigens SurfaceHumoral immunityImmunologybiology.proteinbacteriaFemaleTranscription Factors030215 immunologyJournal of Experimental Medicine
researchProduct

Improved effect of the combination naltrexone/D-penicillamine in the prevention of alcohol relapse-like drinking in rats

2014

Opioid antagonists are licensed drugs for treating alcohol use disorders; nonetheless, clinical studies have evidenced their limited effectiveness. Preclinical findings indicate that opioid receptor (OR) antagonists, such as naltrexone (NTX), reduce the alcohol deprivation effect (ADE). However, a detailed analysis of published data shows the existence of a delayed increase in ethanol consumption after continuous OR blockade, a phenomenon originally called as ‘delayed ADE’. We have recently reported that D-penicillamine (DP) is able to prevent ADE through a mechanism dependent on the inactivation of acetaldehyde, the main metabolite of ethanol. Hypothetically, OR activation would be trigge…

MaleCombination therapyAlcohol Drinkingmedicine.drug_classInjections SubcutaneousNarcotic AntagonistsPharmacologyInfusions SubcutaneousNaltrexoneethanol relapse preventionchemistry.chemical_compoundOpioid receptormedicineSecondary PreventionAnimalsPharmacology (medical)PharmacologyEthanolbusiness.industryPenicillaminePenicillamineD-penicillamineAcetaldehydeNaltrexoneRatsPsychiatry and Mental healthOpioidchemistrymu-opioid receptorDrug Therapy Combinationμ-opioid receptorbusinessnaltrexonehuman activitiesmedicine.drugAlcohol Deterrentsacetaldehyde
researchProduct

Evaluation of intraindividual contrast enhancement variability for determining the maximum achievable consistency in CT

2019

OBJECTIVE. The purpose of this study was to quantify temporal variability in vascular and parenchymal enhancement within the same patient and to determine technique-related factors contributing to this variability. MATERIALS AND METHODS. We identified 100 patients who underwent four CT scans within 12 months with identical acquisition and contrast injection parameters. Enhancement was recorded in the abdominal aorta, main portal vein, liver parenchyma, and subcutaneous fat. Patient demographic and body habitus data were recorded. Injection-related factors were recorded including delay time from contrast injection to image acquisition. All pairwise differences in enhancement within each pati…

MaleContrast enhancementTime Factors030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineConsistency (statistics)MedicineHumansRadiology Nuclear Medicine and imagingAorta AbdominalVariabilityAgedRetrospective StudiesObserver Variationbusiness.industryPortal VeinEnhancementContrast mediaGeneral MedicineMiddle AgedSubcutaneous Fat AbdominalRadiographic Image EnhancementLiver030220 oncology & carcinogenesisFemalebusinessNuclear medicineTomography X-Ray ComputedCT
researchProduct

Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.

2008

The aim of this study was to compare the analgesic and adverse effects, doses, as well as cost of opioid drugs, supportive drug therapy and other analgesic drugs in patients treated with oral sustained-release morphine, transdermal fentanyl, and oral methadone.One hundred and eight cancer patients, no longer responsive to opioids for moderate pain, were selected to randomly receive initial daily doses of 60 mg of oral sustained-release morphine, 15 mg of oral methadone, or 0.6 mg (25 microg/h) of transdermal fentanyl. Oral morphine was used as breakthrough pain medication during opioid titration. Opioid doses, pain intensity, adverse effects, symptomatic drugs, were recorded at week interva…

MaleCost-Benefit AnalysisAdministration OralFentanylNeoplasmscancer pain opioidsProspective StudiesCancer painTransdermalIntractableAnalgesicsMorphineMiddle AgedPain IntractableAnalgesics OpioidFentanylNeuropsychology and Physiological PsychologyTreatment OutcomeNeurologyPatient SatisfactionAnesthesiaAdministrationFemaleDrugmedicine.drugOralAdultAdolescentAnalgesicPainOpioidAdministration CutaneousDrug Administration ScheduleDose-Response RelationshipmedicineHumansAdverse effectAgedDose-Response Relationship Drugbusiness.industryCostsCutaneousAnesthesiology and Pain MedicineOpioidCancer pain; Costs; Fentanyl; Methadone; Morphine; Administration Cutaneous; Administration Oral; Adolescent; Adult; Aged; Analgesia; Analgesics Opioid; Cost-Benefit Analysis; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Fentanyl; Humans; Male; Methadone; Middle Aged; Morphine; Neoplasms; Pain Intractable; Patient Satisfaction; Prospective Studies; Quality of Life; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology; Neuropsychology and Physiological PsychologyMorphineQuality of LifeAnalgesiaCancer painbusinessMethadoneMethadoneEuropean journal of pain (London, England)
researchProduct

Guideline-adherence regarding critical time intervals in the German Chest Pain Unit registry

2020

Background: Since 2008, the German Cardiac Society certified 256 Chest Pain Units (CPUs). Little is known about adherence to recommended performance measures in patients with suspected acute coronary syndrome (ACS) presenting to CPUs. We investigated guideline-adherence regarding critical time intervals and selected performance measures in German Chest Pain Units. Methods: From 2008 to 2014, 23,804 consecutive patients with suspected ACS were prospectively enrolled in the Chest Pain Unit registry of the German Cardiac Society. Results: Median time from symptom onset to first medical contact was 2 h in patients with ST-elevation myocardial infarction (STEMI) and 4 h in patients with unstable…

MaleCritical timeMedizinische Fakultät » Universitätsklinikum Essen » Institut für PathophysiologieTime FactorsMedizin030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineChest painGermanElectrocardiography610 Medical sciences Medicine0302 clinical medicineGermanyProspective StudiesRegistries030212 general & internal medicineNon-ST Elevated Myocardial InfarctionGuideline adherenceGeneral MedicineMiddle AgedHospitalizationlanguageFemaleAcute coronary syndromeGuideline Adherencemedicine.symptomCardiology and Cardiovascular MedicineHospital UnitsChest Painmedicine.medical_specialtyAcute coronary syndromeguideline-adherence61003 medical and health sciencesPercutaneous Coronary Interventiontime intervalsmedicineHumansIn patientddc:610Angina Unstablecardiovascular diseasesAcute Coronary SyndromeAgedbusiness.industryUnstable anginamedicine.diseaseChest Pain Unitlanguage.human_languageEmergency medicineExercise TestST Elevation Myocardial InfarctionTomography X-Ray ComputedbusinessEuropean Heart Journal: Acute Cardiovascular Care
researchProduct

Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, li…

2018

Abstract This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient’s condition, and disease severity or individual complications.

MaleDrug ResistanceReviewCoronary Artery Disease030204 cardiovascular system & hematologySeverity of Illness IndexCoronary artery diseaseEfficacy0302 clinical medicineCardiovascular Diseasecoronary artery abnormalitiesChildCoronary artery abnormalitieSocieties MedicalPediatricAnti-Inflammatory Agents Non-Steroidallcsh:RJ1-570Immunoglobulins IntravenousSettore MED/38Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACardiovascular DiseasesInnovative biotechnologieChild PreschoolPractice Guidelines as TopicFemaleRisk assessmentmedicine.drugHumanmedicine.medical_specialtypediatricsMucocutaneous Lymph Node SyndromeRisk AssessmentFollow-Up Studie03 medical and health sciencesinnovative biotechnologies030225 pediatricsDiabetes mellitusSeverity of illnessmedicineHumansIntensive care medicineIntravenous immunoglobulinAspirinKawasaki diseasebusiness.industryWarfarinlcsh:Pediatricsmedicine.diseasePersonalized medicineInfliximabAspirin; Child; Coronary artery abnormalities; Innovative biotechnologies; Intravenous immunoglobulin; Kawasaki disease; Personalized medicine;Immunoglobulins IntravenouPediatrics Perinatology and Child Healthperinatology and child healthKawasaki diseaseaspirin; child; coronary artery abnormalities; innovative biotechnologies; intravenous immunoglobulin; Kawasaki disease; personalized medicine; pediatrics perinatology and child healthbusinessFollow-Up Studies
researchProduct

The Full Revasc (Ffr-gUidance for compLete non-cuLprit REVASCularization) Registry-based randomized clinical trial

2021

Publisher Copyright: © 2021 Background: Complete revascularization in ST elevation myocardial infarction (STEMI) patients with multivessel disease has resulted in reduction in composite clinical endpoints in medium sized trials. Only one trial showed an effect on hard clinical endpoints, but the revascularization procedure was guided by angiographic evaluation of stenosis severity. Consequently, it is not clear how Fractional Flow Reserve (FFR)-guided percutaneous coronary intervention (PCI) affects hard clinical endpoints in STEMI. Methods and Results: The Ffr-gUidance for compLete non-cuLprit REVASCularization (FULL REVASC) – is a pragmatic, multicenter, international, registry-based rand…

MaleEmergency Medical Servicesmedicine.medical_treatmentFractional flow reserve030204 cardiovascular system & hematologyCoronary AngiographyGUIDELINESSeverity of Illness IndexANGIOGRAPHYDISEASElaw.invention0302 clinical medicineRandomized controlled triallawFRACTIONAL FLOW RESERVEClinical endpointMedicineCardiac and Cardiovascular Systems030212 general & internal medicineRegistriesKardiologiMiddle Aged3. Good healthFractional Flow Reserve MyocardialOutcome and Process Assessment Health CareSurgery Computer-AssistedCardiologyFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyRevascularizationCulpritLESION03 medical and health sciencesPercutaneous Coronary InterventionInternal medicineHumanscardiovascular diseasesMortalityANGIOPLASTYAgedbusiness.industryCoronary StenosisELEVATION MYOCARDIAL-INFARCTIONPercutaneous coronary interventionmedicine.disease3126 Surgery anesthesiology intensive care radiologyStenosis3121 General medicine internal medicine and other clinical medicineConventional PCIST Elevation Myocardial Infarctionbusiness
researchProduct

Higher Free Fatty Acid Uptake in Visceral Than in Abdominal Subcutaneous Fat Tissue in Men

2010

Visceral adipose tissue has been shown to have high lipolytic activity. The aim of this study was to examine whether free fatty acid (FFA) uptake into visceral adipose tissue is enhanced compared to abdominal subcutaneous tissue in vivo. Abdominal adipose tissue FFA uptake was measured using positron emission tomography (PET) and [F-18]-labeled 6-thia-hepta-decanoic acid ([F-18]FTHA) and fat masses using magnetic resonance imaging (MRI) in 18 healthy young adult males. We found that FFA uptake was 30% higher in visceral compared to subcutaneous adipose tissue (0.0025 +/- 0.0018 vs. 0.0020 +/- 0.0016 mu mol/g/min, P = 0.005). Visceral and subcutaneous adipose tissue FFA uptakes were strongly…

MaleEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Adipose tissueWhite adipose tissueFatty Acids NonesterifiedGLUCOSE0302 clinical medicineEndocrinologyReference ValuesIN-VIVOchemistry.chemical_classification0303 health sciencesINSULIN-RESISTANCENutrition and DieteticsFatty AcidsMagnetic Resonance Imagingmedicine.anatomical_structureADIPOSE-TISSUEPROLONGED EXERCISESKELETAL-MUSCLESubcutaneous tissueAdultmedicine.medical_specialtyIntra-Abdominal Fat030209 endocrinology & metabolismIntra-Abdominal FatMETABOLISMYoung Adult03 medical and health sciencesInsulin resistanceInternal medicinemedicineHumansTotal TissueINCREASED PHYSICAL-ACTIVITY030304 developmental biologyBLOOD-FLOWbusiness.industryFatty acidSkeletal muscleBiological Transportmedicine.diseaseSubcutaneous Fat AbdominalEndocrinologychemistryPositron-Emission TomographyRadiopharmaceuticalsbusinessMYOCARDIUMObesity
researchProduct

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countrie…

2015

Summary Background Up-to-date evidence about levels and trends in disease and injury incidence, prevalence, and years lived with disability (YLDs) is an essential input into global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013), we estimated these quantities for acute and chronic diseases and injuries for 188 countries between 1990 and 2013. Methods Estimates were calculated for disease and injury incidence, prevalence, and YLDs using GBD 2010 methods with some important refinements. Results for incidence of acute disorders and prevalence of chronic disorders are new additions to the analysis. Key improvements include expansion to the cause an…

MaleGerontologyNutrition and DiseaseEpidemiologyyears lived with disability Global burden of disease acute and chronic diseases countriesPrevalenceDiseaseGlobal HealthMedical and Health SciencesConduct disorderOtitis-mediaCost of IllnessResidence CharacteristicsVoeding en ZiekteEpidemiologyPrevalence80 and overGlobal health2.2 Factors relating to the physical environment2.1 Biological and endogenous factorscountriesAetiologyChildAged 80 and overMedicine(all)education.field_of_studyATTENTION-DEFICIT/HYPERACTIVITY DISORDERIncidenceMortality rateIncidence (epidemiology)Pain ResearchNeglected DiseasesAlcohol dependenceGeneral MedicineMiddle AgedGlobal burden of diseaseGlobal Burden of Disease Study 2013 CollaboratorsMental HealthInfectious DiseasesAttention deficit/Hyperactivity disorderBurden of IllnessChild PreschoolAcute DiseaseFemaleLife Sciences & BiomedicineAdultmedicine.medical_specialtyAdolescentGBD 2013Populationacute and chronic diseasesYoung AdultMental-disordersAge DistributionMedicine General & InternalWeightsGeneral & Internal MedicinemedicineHumansLife ScienceDisabled PersonsSex DistributionPreschooleducationDeveloping CountriesVLAGAgedScience & Technologybusiness.industryDeveloped CountriesCutaneous LeishmaniasisInfant NewbornInfantHealth outcomesNewbornmedicine.diseaseComorbidityBrain Disordersyears lived with disabilityGood Health and Well BeingDisease injury incidence prevalence YLDs GBD 2010Chronic DiseaseWounds and Injuriesbusiness2.4 Surveillance and distributionIron-deficiencyDemography
researchProduct